ReviewAnnals of global health2019
Curving Tuberculosis: Current Trends and Future Needs.
Review in Annals of global health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 30 citations in OpenAlex.
- Knowledge and Prevalence of Latent Tuberculosis Infection: A Feasibility and Pilot Study in a Primary Healthcare Setting in Rural Eastern Cape, South Africa.International journal of environmental research and public health · 2025Article
- Structural Characterization ofMicroorganisms · 2024Article
- The structure of Mycobacterium thermoresistibile MmpS5 reveals a conserved disulfide bond across mycobacteria.Metallomics : integrated biometal science · 2024Article
- Tuberculosis incidence in Brazil: time series analysis between 2001 and 2021 and projection until 2030.Revista brasileira de epidemiologia = Brazilian journal of epidemiology · 2024Article
- A novel chemokine biomarker to distinguish active tuberculosis from latent tuberculosis: a cohort study.QJM : monthly journal of the Association of Physicians · 2023Article
- Metformin Increases Cell Viability and Regulates Pro-Inflammatory Response to Mtb.Infection and drug resistance · 2023Article
- Recent Progress in the Development of Novel Mycobacterium Cell Wall Inhibitor to Combat Drug-Resistant Tuberculosis.Microbiology insights · 2022Review
- Organoids as a Powerful Model for Respiratory Diseases.Stem cells international · 2020Review
- HAMLET, a protein complex from human milk has bactericidal activity and enhances the activity of antibiotics against pathogenicAntimicrobial agents and chemotherapy · 2019Article
- Antibiotic resistance breakers: current approaches and future directions.FEMS microbiology reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) presents new challenges as a global public health problem, especially at a time of increasing threats to some particular patients due to Human Immunodeficiency Virus (HIV) infection and multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis. The World Health Assembly strives to reduce TB deaths by 95% and to decrease TB incidence by 95% by 2035. However, new approaches are necessary in order to attain these objectives. Such approaches include active ascertainment of cases in high risk populations, increasing the availability of accurate point-of-care testing, rapid detection of drug resistance, novel vaccines, and new prophylaxis and treatment regimens (particularly for MDR and XDR TB). The ultimate objective of those programs is to develop highly effective drug regimens that can achieve high cure rates regardless of strains' resistance patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.